Antibody Discovery Market
Upcoming research reports. Delivery timeline: 4 weeks
The global antibody discovery market, valued at US$XX billion in 2023, is forecasted to grow at a robust CAGR of XX%, reaching US$XX billion in 2024 and an impressive US$XX billion by 2029. The major factors driving the growth of this market are technological advancements in the sequencing technology for antibody discovery, rising investment for antibody drug discovery services, expanding use of monoclonal antibodies in therapeutics, diagnostics and research, increasing prevalence of chronic and infectious disease and rising interest in novel modalities such as antibody-drug conjugates, and bispecific antibodies.
Attractive Opportunities in Antibody Discovery Market
Global Antibody Discovery Market Dynamics
Driver: Rising investment for antibody discovery services
The expanding utilisation of antibody drug discovery services and platforms has garnered considerable investor interest, resulting in a notable increase in investment activity. These funding are facilitating the advancement of next-generation antibody discovery platforms, essential for the creation of innovative antibody-based medicines and the promotion of market expansion.
numerous firms are growing through mergers and acquisitions. For instance,In March 2023, Twist Bioscience (US) introduced antibody discovery services through its subsidiary, Twist Biopharma Solutions, following the acquisition of Abveris (US), an antibody discovery CRO, in 2022.
In March 2021, Antiverse (UK) secured USD 2 million in seed funding to advance an AI-based platform for therapeutic antibody development. LabGenius (UK) secured USD 42 million in a Series B fundraising round in May 2024, increasing its total funding to USD 70 million.
Antibody Solutions (US), a provider of antibody discovery services, secured a USD 1.2 million grant from the Bill & Melinda Gates Foundation to create reagents for expedited malaria diagnostic tests, targeting challenges related to specificity and sensitivity in existing rapid diagnostic tests (RDTs).
These initiatives and progress are substantially propelling the antibody discovery market, promoting innovation, and facilitating the creation of advanced therapies to meet unfulfilled medical requirements.
Restraint: Stringent approval processes and compliance requirements for biologics and biosimilars.
The antibody discovery market is restrained by the stringent regulatory requirements for the development and approval of antibody-based therapeutics. Regulatory agencies, including the US FDA, EMA, and Japan's PMDA, implement regulations which are frequently more complex than small-molecule API. In the development of antibody drugs, there are extensive preclinical and clinical trial phases. For Instance, Phase 1 trials, which typically involve only 10–50 participants, are dedicated to the identification of safe dosages and the resolution of ethical concerns, particularly in the field of oncology. In order to demonstrate clinical benefits such as progression-free survival, later phases, such as Phase 3, need substantial investments and large number of participants, which results in a substantial increase in costs and timelines.
Biologics come under more strict manufacturing rules than small molecule APIs. Standards such as ICH Q11 and Q6B demand strong quality control mechanisms, which raises production's complexity and expense of manufacture. Further raising the development obstacles, 'The Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use' of the US FDA highlight the need of doing thorough testing to guarantee the safety, immunogenicity, and consistency of the manufacturing process.
The complicated character of biologics, including monoclonal antibodies, and the great risk of manufacturing variability help to explain their somewhat low approval rates. Usually spanning a decade, the overall development expenses are more than USD 1 billion. These challenges prevent smaller companies from entering the market, therefore limiting innovation and competitiveness. These legislative actions create significant challenges that hinder the growth of the antibody discovery business even if they ensure patient safety.
Opportunity: Rising Interest in Novel Modalities like ADCs and Bispecific Antibodies
For the antibody discovery market, the increasing acceptance of creative methods including antibody-drug conjugates (ADCs), bispecific antibodies, and nanobodies offers a great potential. Combining strong cytotoxic drugs with the accuracy of monoclonal antibodies, ADCs provide focused cancer treatments with lowered off-target damage. With 11 FDA-approved ADCs to date and more than 1,000 ADCs in many phases of research, ADC technology has evolved dramatically over the years. These figures capture the huge potential and great momentum of this class of treatments.
Another field of fast development are bispecific antibodies, which may attach to two different antigens or epitopes concurrently. Of the 50 new CDER approvals in 2024, 20% were monoclonal antibodies and 6% were bispecific antibodies, demonstrating their expanding
The increased success rates of these novel approaches and their expanding pipeline give antibody discovery firms with several potential to develop better platforms and broaden their service offerings.
Challenge: Emerging antibody alternatives as treatment modalities
The rise of non-antibody-based modalities, including antibody mimetics, aptamers, and scaffold proteins, poses an increasing challenge to the antibody discovery sector. These alternatives are designed to mimic or surpass conventional antibodies, providing advantages such as economical production, scalability, and less variability. A variety of mimetics can be synthesised in bacterial systems, circumventing the necessity for intricate post-translational modifications and costly production techniques.
Synthetic reagents, such as aptamers and molecularly imprinted polymers (MIPs), are increasingly favoured for their exceptional specificity, stability, and capacity to bind challenging or non-immunogenic targets. In contrast to antibodies generated from animals, they mitigate performance variability and ethical issues related to animal utilisation. Their swift advancement and broadening applications in diagnostics and research are redirecting investments and focus from conventional antibody discovery platforms.
Although antibodies continue to be the standard for numerous therapeutic applications, these rising alternatives are compelling the antibody discovery market to evolve and innovate in order to sustain its competitive advantage.
Key Market Players
Creative BioLabs (US),
Evotec (Germany),
Bruker (US),
Biocytogen (US),
Charles River Laboratries (US),
Aragen Life Sciences Ltd. (India),
Biodura-Sundia (US),
Twist Bioscience (US),
NanoCellect Biomedical (US),
Sartorius AG (Germany),
Bio-Rad Laboratries, Inc. (US).
Recent Developments:
In January 2025, Biocytogen (US) licensed its fully human antibodies to Sotio (Czech Republic) for developing SOT109, a novel ADC aimed at treating colorectal and gastrointestinal cancers.
In January 2025, Biocytogen (US) and Acepodia (US) announced a strategic partnership to develop dual-payload bispecific antibody-drug conjugates (BsAD2Cs) for complex tumor treatments. The collaboration combines Biocytogen’s RenLite platform with Acepodia’s Antibody-Dual-Drugs Conjugation (AD2C) technology.
In November 2024, Charles River Laboratories (US) and NJ Bio (US) formed a strategic alliance to enhance ADC development and manufacturing services. This partnership combines expertise in engineered antibodies and linker-payload synthesis for improved ADC safety and efficacy.
In October 2024, Twist Bioscience (US) and Absci (US) joined forces to leverage AI and DNA synthesis technologies for accelerated antibody discovery and the development of treatments for unmet medical needs.
In October 2023, Twist Bioscience (US) partnered with Bayer AG (Germany) to develop and license antibodies, with Twist eligible for up to USD 188 million in milestone payments and royalties for clinical and commercial success.
In August 2024, Aragen Life Sciences Ltd. (India) signed an MoU with Merck KGaA (Germany) to accelerate mAb process development and manufacturing timelines, supporting clinical-to-commercial scale-up.
In July 2024, Biocytogen (US) entered into an agreement with Sotio (Czech Republic) for up to $326 million to develop bispecific ADCs targeting solid tumors. This deal leverages Biocytogen’s transgenic mice to create innovative resistance-busting molecules
In June 2024, Just – Evotec Biologics, a subsidiary of Evotec (Germany), secured a USD 39 million multiyear contract from the U.S. Department of Defense to develop a monoclonal antibody (mAb) manufacturing framework. This initiative aims to enhance rapid response capabilities for biologics medical countermeasures.
The global antibody discovery market, valued at US$XX billion in 2023, is forecasted to grow at a robust CAGR of XX%, reaching US$XX billion in 2024 and an impressive US$XX billion by 2029. The major factors driving the growth of this market are technological advancements in the sequencing technology for antibody discovery, rising investment for antibody drug discovery services, expanding use of monoclonal antibodies in therapeutics, diagnostics and research, increasing prevalence of chronic and infectious disease and rising interest in novel modalities such as antibody-drug conjugates, and bispecific antibodies.
Attractive Opportunities in Antibody Discovery Market
Global Antibody Discovery Market Dynamics
Driver: Rising investment for antibody discovery services
The expanding utilisation of antibody drug discovery services and platforms has garnered considerable investor interest, resulting in a notable increase in investment activity. These funding are facilitating the advancement of next-generation antibody discovery platforms, essential for the creation of innovative antibody-based medicines and the promotion of market expansion.
numerous firms are growing through mergers and acquisitions. For instance,In March 2023, Twist Bioscience (US) introduced antibody discovery services through its subsidiary, Twist Biopharma Solutions, following the acquisition of Abveris (US), an antibody discovery CRO, in 2022.
In March 2021, Antiverse (UK) secured USD 2 million in seed funding to advance an AI-based platform for therapeutic antibody development. LabGenius (UK) secured USD 42 million in a Series B fundraising round in May 2024, increasing its total funding to USD 70 million.
Antibody Solutions (US), a provider of antibody discovery services, secured a USD 1.2 million grant from the Bill & Melinda Gates Foundation to create reagents for expedited malaria diagnostic tests, targeting challenges related to specificity and sensitivity in existing rapid diagnostic tests (RDTs).
These initiatives and progress are substantially propelling the antibody discovery market, promoting innovation, and facilitating the creation of advanced therapies to meet unfulfilled medical requirements.
Restraint: Stringent approval processes and compliance requirements for biologics and biosimilars.
The antibody discovery market is restrained by the stringent regulatory requirements for the development and approval of antibody-based therapeutics. Regulatory agencies, including the US FDA, EMA, and Japan's PMDA, implement regulations which are frequently more complex than small-molecule API. In the development of antibody drugs, there are extensive preclinical and clinical trial phases. For Instance, Phase 1 trials, which typically involve only 10–50 participants, are dedicated to the identification of safe dosages and the resolution of ethical concerns, particularly in the field of oncology. In order to demonstrate clinical benefits such as progression-free survival, later phases, such as Phase 3, need substantial investments and large number of participants, which results in a substantial increase in costs and timelines.
Biologics come under more strict manufacturing rules than small molecule APIs. Standards such as ICH Q11 and Q6B demand strong quality control mechanisms, which raises production's complexity and expense of manufacture. Further raising the development obstacles, 'The Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use' of the US FDA highlight the need of doing thorough testing to guarantee the safety, immunogenicity, and consistency of the manufacturing process.
The complicated character of biologics, including monoclonal antibodies, and the great risk of manufacturing variability help to explain their somewhat low approval rates. Usually spanning a decade, the overall development expenses are more than USD 1 billion. These challenges prevent smaller companies from entering the market, therefore limiting innovation and competitiveness. These legislative actions create significant challenges that hinder the growth of the antibody discovery business even if they ensure patient safety.
Opportunity: Rising Interest in Novel Modalities like ADCs and Bispecific Antibodies
For the antibody discovery market, the increasing acceptance of creative methods including antibody-drug conjugates (ADCs), bispecific antibodies, and nanobodies offers a great potential. Combining strong cytotoxic drugs with the accuracy of monoclonal antibodies, ADCs provide focused cancer treatments with lowered off-target damage. With 11 FDA-approved ADCs to date and more than 1,000 ADCs in many phases of research, ADC technology has evolved dramatically over the years. These figures capture the huge potential and great momentum of this class of treatments.
Another field of fast development are bispecific antibodies, which may attach to two different antigens or epitopes concurrently. Of the 50 new CDER approvals in 2024, 20% were monoclonal antibodies and 6% were bispecific antibodies, demonstrating their expanding
The increased success rates of these novel approaches and their expanding pipeline give antibody discovery firms with several potential to develop better platforms and broaden their service offerings.
Challenge: Emerging antibody alternatives as treatment modalities
The rise of non-antibody-based modalities, including antibody mimetics, aptamers, and scaffold proteins, poses an increasing challenge to the antibody discovery sector. These alternatives are designed to mimic or surpass conventional antibodies, providing advantages such as economical production, scalability, and less variability. A variety of mimetics can be synthesised in bacterial systems, circumventing the necessity for intricate post-translational modifications and costly production techniques.
Synthetic reagents, such as aptamers and molecularly imprinted polymers (MIPs), are increasingly favoured for their exceptional specificity, stability, and capacity to bind challenging or non-immunogenic targets. In contrast to antibodies generated from animals, they mitigate performance variability and ethical issues related to animal utilisation. Their swift advancement and broadening applications in diagnostics and research are redirecting investments and focus from conventional antibody discovery platforms.
Although antibodies continue to be the standard for numerous therapeutic applications, these rising alternatives are compelling the antibody discovery market to evolve and innovate in order to sustain its competitive advantage.
Key Market Players
Creative BioLabs (US),
Evotec (Germany),
Bruker (US),
Biocytogen (US),
Charles River Laboratries (US),
Aragen Life Sciences Ltd. (India),
Biodura-Sundia (US),
Twist Bioscience (US),
NanoCellect Biomedical (US),
Sartorius AG (Germany),
Bio-Rad Laboratries, Inc. (US).
Recent Developments:
In January 2025, Biocytogen (US) licensed its fully human antibodies to Sotio (Czech Republic) for developing SOT109, a novel ADC aimed at treating colorectal and gastrointestinal cancers.
In January 2025, Biocytogen (US) and Acepodia (US) announced a strategic partnership to develop dual-payload bispecific antibody-drug conjugates (BsAD2Cs) for complex tumor treatments. The collaboration combines Biocytogen’s RenLite platform with Acepodia’s Antibody-Dual-Drugs Conjugation (AD2C) technology.
In November 2024, Charles River Laboratories (US) and NJ Bio (US) formed a strategic alliance to enhance ADC development and manufacturing services. This partnership combines expertise in engineered antibodies and linker-payload synthesis for improved ADC safety and efficacy.
In October 2024, Twist Bioscience (US) and Absci (US) joined forces to leverage AI and DNA synthesis technologies for accelerated antibody discovery and the development of treatments for unmet medical needs.
In October 2023, Twist Bioscience (US) partnered with Bayer AG (Germany) to develop and license antibodies, with Twist eligible for up to USD 188 million in milestone payments and royalties for clinical and commercial success.
In August 2024, Aragen Life Sciences Ltd. (India) signed an MoU with Merck KGaA (Germany) to accelerate mAb process development and manufacturing timelines, supporting clinical-to-commercial scale-up.
In July 2024, Biocytogen (US) entered into an agreement with Sotio (Czech Republic) for up to $326 million to develop bispecific ADCs targeting solid tumors. This deal leverages Biocytogen’s transgenic mice to create innovative resistance-busting molecules
In June 2024, Just – Evotec Biologics, a subsidiary of Evotec (Germany), secured a USD 39 million multiyear contract from the U.S. Department of Defense to develop a monoclonal antibody (mAb) manufacturing framework. This initiative aims to enhance rapid response capabilities for biologics medical countermeasures.
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2.1 INSIGHTS FROM PRIMARY
2.2.2 SEGMENT ASSESSMENT METHODOLOGY
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 LIMITATIONS
2.7 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
5.4.2 AVERAGE SELLING PRICE TREND, BY REGION
5.5 SUPPLY CHAIN ANALYSIS
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 IMPACT OF AI/GEN AI
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.3 ADJACENT TECHNOLOGIES
5.10 PATENT ANALYSIS
5.11 KEY CONFERENCES & EVENTS 2024-2025
5.12 REGULATORY LANDSCAPE
5.12.1 REGULATORY SCENARIO
5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
5.13 PORTER’S FIVE FORCES ANALYSIS
5.13.1 THREAT OF NEW ENTRANTS
5.13.2 THREAT OF SUBSTITUTE
5.13.3 BARGAINING POWER OF SUPPLIERS
5.13.4 BARGAINING POWER OF BUYERS
5.13.5 INTENSITY OF COMPETITION RIVALRY
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN THE BUYING PROCESS
5.14.2 BUYING CRITERIA FOR END USERS
5.15 INVESTMENT AND FUNDING SCENARIO
6 ANTIBODY DISCOVERY MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 PRODUCT
6.2.1 ANTIBODY DISCOVERY PLATFORMS & SYSTEMS
6.2.2 KITS & REAGENTS
6.2.3 ANTIBODY LIBRARIES
6.2.3 OTHER PRODUCTS (INCLUDES RESIN, PROTEINS, CELL LINES, & OTHER PRODUCTS)
6.3 SERVICE
6.3.1 ANTIBODY SCREENING/DETECTION SERVICES
6.3.2 ANTIBODY ENGINEERING AND OPTIMIZATION SERVICES
6.3.3 PRECLINICAL AND CLINICAL DEVELOPMENT SERVICES
6.3.4 OTHER SERVICES (IF ANY)
7 ANTIBODY DISCOVERY MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
7.2 PHAGE DISPLAY TECHNOLOGY
7.3 HYBRIDOMA TECHNOLOGY
7.4 SINGLE-CELL TECHNOLOGIES
7.5 OTHER TECHNOLOGIES (INCLUDES MICROFLUIDICS, HUMANIZED TECHNOLOGIES)
*The above inclusions for Other Technologies segment are subject to change during research.
8 ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE
8.1 INTRODUCTION
8.2 MONOCLONAL ANTIBODIES (MABS)
8.3 POLYCLONAL ANTIBODIES
8.4 OTHER ANTIBODY TYPES (BISPECIFIC ANTIBODIES, NANOBODIES)
*The above inclusions for Other Types segment are subject to change during research.
9 ANTIBODY DISCOVERY MARKET, BY NATURE
9.1 INTRODUCTION
9.2 CHIMERIC
9.3 HUMANIZED
9.4 RECOMBINANT
9.5 OTHERS (IF ANY)
10 ANTIBODY DISCOVERY MARKET, BY END USER
10.1 INTRODUCTION
10.2 PHARMACEUTICAL COMPANIES & BIOTECHNOLOGY COMPANIES
10.3 ACADEMIC & RESEARCH INSTITUTES
10.4 OTHER END USERS (HOSPITALS, DIAGNOSTIC LABORATRIES)
*The above inclusions for Other End Users segment are subject to change during research.
11 ANTIBODY DISCOVERY MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2 US
11.2.3 CANADA
11.3 EUROPE
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2 GERMANY
11.3.3 FRANCE
11.3.4 UK
11.3.5 ITALY
11.3.6 SPAIN
11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2 JAPAN
11.4.3 CHINA
11.4.4 INDIA
11.4.5 SOUTH KOREA
11.4.6 AUSTRALIA
11.4.7 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2 BRAZIL
11.5.3 REST OF LATIN AMERICA
11.6 MIDDLE EAST
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
11.6.2 GCC
11.6.2.1 SAUDI ARABIA (KSA)
11.6.2.2 UNITED ARAB EMIRATES (UAE)
11.6.2.3 REST OF GCC
11.6.3 REST OF MIDDLE EAST
11.7 AFRICA
11.7.1 MACROECONOMIC OUTLOOK FOR AFRICA
NOTE 1: REST OF EUROPE INCLUDES SWITZERLAND, RUSSIA, PORTUGAL, POLAND, NETHERLANDS, FINLAND, DENMARK, BELGIUM, AUSTRIA, HUNGARY, ICELAND, IRELAND, NORWAY, AND LUXEMBOURG
NOTE 2: REST OF ASIA PACIFIC INCLUDES BANGLADESH, BHUTAN, NEPAL, SRI LANKA, PHILIPPINES, SINGAPORE, VIETNAM, THAILAND, TAIWAN, CAMBODIA, AND INDONESIA
NOTE 3: REST OF LATIN AMERICA INCLUDES MEXICO, COLOMBIA, ECUADOR, PERU, URUGUAY, CUBA AND CHILE
NOTE 4: REST OF GCC INCLUDES BAHRAIN, KUWAIT, AND OMAN
NOTE 5: INCLUSIONS AND FURTHER GEOGRAPHICAL SEGMENTATION WILL DEPEND ON MARKET SIZE.
12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 KEY PLAYERS STRATEGIES/ RIGHT TO WIN
12.3 REVENUE SHARE ANALYSIS (TOP PLAYERS)
12.4 MARKET SHARE ANALYSIS (TOP PLAYERS)
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS
12.5.5.1 COMPANY FOOTPRINT
12.5.5.2 TYPE FOOTPRINT
12.5.5.3 TECHNOLOGY FOOTPRINT
12.5.5.4 NATURE FOOTPRINT
12.5.5.5 REGION FOOTPRINT
12.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
12.6.5.1 DETAILED LIST OF KEY STARTUPS/ SMES
12.6.5.2 COMPETITIVE BENCHMARKING OF KEY STARTUPS/ SMES
12.7 COMPETITIVE SCENARIO
12.7.1 DEALS
12.7.2 OTHER DEVELOPMENTS
12.8 BRAND/ PRODUCT COMPARATIVE ANALYSIS
12.9 VENDOR VALUATION AND FINANCIAL METRICS OF THE ANTIBODY DISCOVERY MARKET
13 COMPANY PROFILES
13.1 KEY COMPANIES
13.1.1 CREATIVE BIOLABS
13.1.2 EVOTEC
13.1.3 BRUKER
13.1.4 BIOCYTOGEN
13.1.5 CHARLES RIVER LABORATRIES
13.1.6 ARAGEN LIFE SCIENCES LTD.
13.1.7 BIODURO-SUNDIA
13.1.8 TWIST BIOSCIENCE
13.1.9 NANOCELLECT BIOMEDICAL
13.1.10 SARTORIUS AG
13.1.11 BIO-RAD LABORATORIES, INC.
13.2 OTHER PLAYERS
Note: The provided list of players is tentative and subject to change during the research. Details on business overview, financial information (based on availability), product portfolio, and recent developments will be provided for 20-25 companies.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2.1 INSIGHTS FROM PRIMARY
2.2.2 SEGMENT ASSESSMENT METHODOLOGY
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 LIMITATIONS
2.7 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.2 RESTRAINTS
5.2.3 OPPORTUNITIES
5.2.4 CHALLENGES
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
5.4.2 AVERAGE SELLING PRICE TREND, BY REGION
5.5 SUPPLY CHAIN ANALYSIS
5.6 VALUE CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 IMPACT OF AI/GEN AI
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.3 ADJACENT TECHNOLOGIES
5.10 PATENT ANALYSIS
5.11 KEY CONFERENCES & EVENTS 2024-2025
5.12 REGULATORY LANDSCAPE
5.12.1 REGULATORY SCENARIO
5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
5.13 PORTER’S FIVE FORCES ANALYSIS
5.13.1 THREAT OF NEW ENTRANTS
5.13.2 THREAT OF SUBSTITUTE
5.13.3 BARGAINING POWER OF SUPPLIERS
5.13.4 BARGAINING POWER OF BUYERS
5.13.5 INTENSITY OF COMPETITION RIVALRY
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN THE BUYING PROCESS
5.14.2 BUYING CRITERIA FOR END USERS
5.15 INVESTMENT AND FUNDING SCENARIO
6 ANTIBODY DISCOVERY MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 PRODUCT
6.2.1 ANTIBODY DISCOVERY PLATFORMS & SYSTEMS
6.2.2 KITS & REAGENTS
6.2.3 ANTIBODY LIBRARIES
6.2.3 OTHER PRODUCTS (INCLUDES RESIN, PROTEINS, CELL LINES, & OTHER PRODUCTS)
6.3 SERVICE
6.3.1 ANTIBODY SCREENING/DETECTION SERVICES
6.3.2 ANTIBODY ENGINEERING AND OPTIMIZATION SERVICES
6.3.3 PRECLINICAL AND CLINICAL DEVELOPMENT SERVICES
6.3.4 OTHER SERVICES (IF ANY)
7 ANTIBODY DISCOVERY MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
7.2 PHAGE DISPLAY TECHNOLOGY
7.3 HYBRIDOMA TECHNOLOGY
7.4 SINGLE-CELL TECHNOLOGIES
7.5 OTHER TECHNOLOGIES (INCLUDES MICROFLUIDICS, HUMANIZED TECHNOLOGIES)
*The above inclusions for Other Technologies segment are subject to change during research.
8 ANTIBODY DISCOVERY MARKET, BY ANTIBODY TYPE
8.1 INTRODUCTION
8.2 MONOCLONAL ANTIBODIES (MABS)
8.3 POLYCLONAL ANTIBODIES
8.4 OTHER ANTIBODY TYPES (BISPECIFIC ANTIBODIES, NANOBODIES)
*The above inclusions for Other Types segment are subject to change during research.
9 ANTIBODY DISCOVERY MARKET, BY NATURE
9.1 INTRODUCTION
9.2 CHIMERIC
9.3 HUMANIZED
9.4 RECOMBINANT
9.5 OTHERS (IF ANY)
10 ANTIBODY DISCOVERY MARKET, BY END USER
10.1 INTRODUCTION
10.2 PHARMACEUTICAL COMPANIES & BIOTECHNOLOGY COMPANIES
10.3 ACADEMIC & RESEARCH INSTITUTES
10.4 OTHER END USERS (HOSPITALS, DIAGNOSTIC LABORATRIES)
*The above inclusions for Other End Users segment are subject to change during research.
11 ANTIBODY DISCOVERY MARKET, BY REGION
11.1 INTRODUCTION
11.2 NORTH AMERICA
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
11.2.2 US
11.2.3 CANADA
11.3 EUROPE
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
11.3.2 GERMANY
11.3.3 FRANCE
11.3.4 UK
11.3.5 ITALY
11.3.6 SPAIN
11.3.7 REST OF EUROPE
11.4 ASIA PACIFIC
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
11.4.2 JAPAN
11.4.3 CHINA
11.4.4 INDIA
11.4.5 SOUTH KOREA
11.4.6 AUSTRALIA
11.4.7 REST OF ASIA PACIFIC
11.5 LATIN AMERICA
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
11.5.2 BRAZIL
11.5.3 REST OF LATIN AMERICA
11.6 MIDDLE EAST
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
11.6.2 GCC
11.6.2.1 SAUDI ARABIA (KSA)
11.6.2.2 UNITED ARAB EMIRATES (UAE)
11.6.2.3 REST OF GCC
11.6.3 REST OF MIDDLE EAST
11.7 AFRICA
11.7.1 MACROECONOMIC OUTLOOK FOR AFRICA
NOTE 1: REST OF EUROPE INCLUDES SWITZERLAND, RUSSIA, PORTUGAL, POLAND, NETHERLANDS, FINLAND, DENMARK, BELGIUM, AUSTRIA, HUNGARY, ICELAND, IRELAND, NORWAY, AND LUXEMBOURG
NOTE 2: REST OF ASIA PACIFIC INCLUDES BANGLADESH, BHUTAN, NEPAL, SRI LANKA, PHILIPPINES, SINGAPORE, VIETNAM, THAILAND, TAIWAN, CAMBODIA, AND INDONESIA
NOTE 3: REST OF LATIN AMERICA INCLUDES MEXICO, COLOMBIA, ECUADOR, PERU, URUGUAY, CUBA AND CHILE
NOTE 4: REST OF GCC INCLUDES BAHRAIN, KUWAIT, AND OMAN
NOTE 5: INCLUSIONS AND FURTHER GEOGRAPHICAL SEGMENTATION WILL DEPEND ON MARKET SIZE.
12 COMPETITIVE LANDSCAPE
12.1 INTRODUCTION
12.2 KEY PLAYERS STRATEGIES/ RIGHT TO WIN
12.3 REVENUE SHARE ANALYSIS (TOP PLAYERS)
12.4 MARKET SHARE ANALYSIS (TOP PLAYERS)
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
12.5.1 STARS
12.5.2 EMERGING LEADERS
12.5.3 PERVASIVE PLAYERS
12.5.4 PARTICIPANTS
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS
12.5.5.1 COMPANY FOOTPRINT
12.5.5.2 TYPE FOOTPRINT
12.5.5.3 TECHNOLOGY FOOTPRINT
12.5.5.4 NATURE FOOTPRINT
12.5.5.5 REGION FOOTPRINT
12.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023
12.6.1 PROGRESSIVE COMPANIES
12.6.2 RESPONSIVE COMPANIES
12.6.3 DYNAMIC COMPANIES
12.6.4 STARTING BLOCKS
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
12.6.5.1 DETAILED LIST OF KEY STARTUPS/ SMES
12.6.5.2 COMPETITIVE BENCHMARKING OF KEY STARTUPS/ SMES
12.7 COMPETITIVE SCENARIO
12.7.1 DEALS
12.7.2 OTHER DEVELOPMENTS
12.8 BRAND/ PRODUCT COMPARATIVE ANALYSIS
12.9 VENDOR VALUATION AND FINANCIAL METRICS OF THE ANTIBODY DISCOVERY MARKET
13 COMPANY PROFILES
13.1 KEY COMPANIES
13.1.1 CREATIVE BIOLABS
13.1.2 EVOTEC
13.1.3 BRUKER
13.1.4 BIOCYTOGEN
13.1.5 CHARLES RIVER LABORATRIES
13.1.6 ARAGEN LIFE SCIENCES LTD.
13.1.7 BIODURO-SUNDIA
13.1.8 TWIST BIOSCIENCE
13.1.9 NANOCELLECT BIOMEDICAL
13.1.10 SARTORIUS AG
13.1.11 BIO-RAD LABORATORIES, INC.
13.2 OTHER PLAYERS
Note: The provided list of players is tentative and subject to change during the research. Details on business overview, financial information (based on availability), product portfolio, and recent developments will be provided for 20-25 companies.
14 APPENDIX
14.1 DISCUSSION GUIDE
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
14.3 AVAILABLE CUSTOMIZATIONS
14.4 RELATED REPORTS
14.5 AUTHOR DETAILS
